Prof Sanjay Popat  speaks to ecancer about cohort 2 of the Beamion LUNG-1 phase Ib trial that evaluated zongertinib, an irreversible HER2-selective tyrosine kinase inhibitor, in treatment-naïve patients with advanced HER2-mutant non-small cell lung cancer (NSCLC).

Among 74 patients, the objective response rate was 77%, including 8% complete responses and 69% partial responses, with a disease control rate of 96%. Six-month progression-free survival and duration of response were 79% and 80%, respectively.

Dr Popat highlights that these results demonstrate strong clinical activity and a favourable safety profile for zongertinib as a first-line therapy, supporting its further evaluation in the phase III Beamion LUNG-2 study.